Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Telix Pharmaceuticals ( (AU:TLX) ) has provided an announcement.
Telix Pharmaceuticals Limited has announced the quotation of 133,825 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code TLX. This move is part of the company’s strategy to enhance its capital structure and support its growth initiatives, potentially strengthening its market position and providing new opportunities for stakeholders.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company is primarily involved in creating innovative solutions for cancer treatment and imaging, aiming to improve patient outcomes and healthcare efficiency.
Average Trading Volume: 1,608,654
Technical Sentiment Signal: Buy
Current Market Cap: A$8.63B
See more insights into TLX stock on TipRanks’ Stock Analysis page.